Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 481

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

COVID-19 and the liver: little cause for concern

Open access
Bangash, Mansoor N, Patel, Jaimin, Parekh, Dhruv·2020·The Lancet Gastroenterology & Hepatology

Abstract

The largest study on COVID-19 to date showed that the prevalence of elevated aminotransferases and bilirubin in people faring worst was at least double that of others. Although clinically significant liver dysfunction was not quantified, this and other studies have led some to suggest that this finding might present clinical challenges. Close inspection of the available data supports a higher prevalence of abnormal aminotransferase levels in severe COVID-19 disease, but these studies actually suggest that clinically significant liver injury is uncommon, even when data for the most severely ill patients are selected (table). Although high levels of positive end expiratory pressure can contribute to hepatic congestion by increasing right atrial pressure and impeding venous return, data suggest that many patients admitted to hospital with COVID-19 have liver blood test abnormalities without mechanical ventilation. Furthermore, the distribution of aminotransferase levels among patients with COVID-19 do not support hypoxic hepatitis being a common phenomenon, according to the published literature. Drug-induced liver injury is a possible contributing factor to the observed abnormal liver blood test abnormalities after therapeutics begin and should be considered by clinicians, but mild liver test derangement is present at baseline in many patients with COVID-19 before significant medication use. Several studies have reported elevated levels of creatinine kinase and lactate dehydrogenase or myoglobin in association with COVID-19 severity (table). It is therefore possible that aminotransferase elevations do not necessarily arise from the liver alone and that COVID-19 infection might induce a myositis similar to that observed in severe influenza infections. It has been proposed that COVID-19 causes direct liver injury via a viral hepatitis, but we believe that there are alternative explanations. First, the derangement of liver function is clearly mild. Second, when liver function tests for patients with different durations of symptoms are examined, there is no evidence that later presentation is associated with greater liver function derangement. The only post-mortem liver biopsy from a patient with COVID-19 showed only microvesicular steatosis, a common finding in sepsis. Most importantly, other respiratory viruses produce similar elevations of liver function biomarkers, which is thought to relate to hepatic damage from immune interactions involving intrahepatic cytotoxic T cells and Kupffer cells. This phenomenon waxes and wanes in parallel with respiratory viral disease and in the absence of hepatic viral replication, which might explain why worse outcomes were not seen in the 42 patients with chronic liver disease and COVID-19 who had outcome data (table). Hepatic dysfunction in severe COVID-19 is accompanied by greater activation of coagulative and fibrinolytic pathways, relatively depressed platelet counts, climbing neutrophil counts and neutrophil to lymphocyte ratios, and high ferritin levels. Although these markers are seen as non-specific markers of inflammation, we believe that they fit the paradigm of disease severity coinciding with a failure of innate immune regulation. Such unbalanced immunity favours NETosis and coagulation activation and possibly also alters systemic iron metabolism secondary to macrophage activation. Notably, this alteration of immune balance occurs with increased age, and older patients might therefore be expected to fare worse, with a greater reliance on this pathway. Clinicians cannot be complacent about the risks of COVID-19 in patients with chronic liver diseases and cirrhosis, because these patients have poor immune function and worse outcomes from acute respiratory distress syndrome than the rest of the critically ill

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(20)30084-4

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 481

Metadata

Authors
Bangash, M. N., Patel, J., & Parekh, D.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2020-06
Volume
5
Issue
6
Pages
529-530
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W3011408171
Cited by
481
References
15
FWCI
13.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 and the liver: little cause for concern. https://app.cochat.ai/papers/10.1016/s2468-1253(20)30084-4
The paper
Bangash, M. N., Patel, J., & Parekh, D. (2020). COVID-19 and the liver: little cause for concern. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(20)30084-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.